Medical Development

Yuory V. Karetnyi M.D., Ph.D.

***** **** ****** *****, *********, VA 20152

Cell: 612-***-**** acv3iv@r.postjobfree.com

Professional Summary

Experienced professional with extensive management experience in microbiology, virology, molecular biology

Extensive Product Development experience within the in-vitro diagnostics (IVD) industry, developing clinical diagnostic products and reagents according to design control/design transfer process

Served as PI and co-PI on multiple occasions of grant and contract submissions involving infectious agents and animal models

Profound knowledge of regulatory requirements in regulated industry, design transfer/design control process, 510k and PMA submissions

Skilled in managing laboratory operations for IVD, in vitro and in vivo detection of viral contaminants for a provider of testing services, overseeing the lab with staff of 8 working on as many as 40 client projects simultaneously. Extensive experience establishing, validating, qualifying, and supervising GLP- and cGMP-regulated testing programs for new and existing customers.

In Vivo animals modeling, In Vitro cell culture, R&D, product development, and testing experience in biotechnology and biopharmaceuticals gained in both industry and academia.

Proven ability to launch new testing programs by designing studies, ensuring compliance with GLP, GMP, GCP and ISO regulations, negotiating testing details with customers, gaining approval for study protocols, supervising testing itself, and overseeing development of reports provided to customers.

Managed group projects for researching and developing FDA-approved diagnostic kits for automated immunoassay, led multiple projects simultaneously, oversaw scientific and technical parts of FDA submissions, and provided support for new product launches.

Proficient and knowledgeable in immunoassay development process, including feasibility, design control, design transfer, validation, qualification, clinical trials and regulatory agency submission.

Industry and Academic Experience

Independent Professional Consulting, Chantilly, Virginia 0/22014-Present

Management, regulation, compliance, quality systems, medical affairs for, IVD infectious diseases programs on various platforms

Professional consulting: R&D, manufacturing, GLP, GMP, GCP, CLIA, CAP, ISO, ICP and operational consulting services for IVD and Bio pharmaceutical organizations.

Roche Diagnostics, Indianapolis, Indiana, 09/2014-06/2015

Global Study Manager (Contract)

Leading IVD infectious diseases programs

Leading the global study team with full accountability for the study with respect to quality, cost and timelines.

Developing study design in coordination with internal/external experts and the development/project team; ensures that global design validation plans are available for design validations/performance evaluations and clinical studies developed in cooperation with internal / external experts and close cooperation with Regulatory affairs.

Ensures that all studies are planned, executed, monitored, closed out and documented in a competent and compliant way within the planned time frame and costs.

Oversight of data management processes, data quality and results and reporting.

Planning and controlling of the study specific content and budget of the studies.

Managing study site and clinical study agreements.

Delegation and oversight of tasks for internal and external collaborators.

Eurofins Medinet Inc., Chantilly, Virginia, 09/2009 – 02/2014

Program Director, Virology

Leading, overseeing and implementing of development, validation, verification, maintenance and performance of IVD assays for the detection and molecular characterization of microorganisms (including bacterial and viral pathogens) in clinical specimens with a heavier focus on viral diagnostics.

Yuory V. Karetnyi M.D., Ph.D. Page 2

Responsible for development and revenue generation including writing of proposals to sponsors.

Responsible for teams management and results generation in a timely manner according to client expectations, development of appropriate staff training programs, and international global collaborations with other laboratories within the Eurofins Medinet network.

Responsible in collaboration with the Chief Scientific Officer (CSO) of development and implementation strategy for global leadership in laboratory and consultative services that support the biopharmaceutical industry’s development of products for preventing, diagnosing, controlling, and treating infectious diseases caused by viruses.

Providing supervision, technical guidance and problem solving on all virology based and molecular assays.

Manage developing and/or maintaining quality standards that meet CAP and CLIA requirements for accreditation of molecular diagnostic testing and virology laboratories.

Identifying and pursuing new opportunities in clinical virology with the goal to support the global expansion of infectious disease services. Introducing commercially available assays and instrumentation in order to ensure that the laboratory is operating on current technology and platforms.

Interacting with clients and internal scientific and sales staff to develop proposals and guidance on laboratory capabilities. Ensuring that the virology and molecular biology functions within the program are adequately resourced and equipped to meet the current and future needs of Eurofins Medinet.

Started up and managed virology/molecular biology operations, currently generating revenue over of $ 1 million annually.

WuXi AppTec Laboratory Services Inc., St. Paul, Minnesota, 06/2004 – 08/2008

Director of Microbiology and In Life Virology

Reporting directly to the VP of Toxicology, oversee in vitro and in vivo detection of viral contaminants and general safety programs for this provider of testing services to customers in the biopharmaceutical and medical device industries and assist with budget development for a $500K budget.

Manage laboratory operations in CRO environment generating revenue over of $ 4 million annually, leading a staff of up to 8 scientists, research associates and technicians in working on up to 40 projects client projects concurrently.

Establish, validate, qualify, and supervise GLP- and cGMP-regulated testing programs for new and existing customers regarding in vitro and in vivo viral contamination testing.

Launch new testing programs for customers by designing studies, ensuring compliance with GLP, GMP and ISO regulations, negotiating testing details with customers, gaining approval for study protocols, supervising testing itself, and overseeing development of reports provided to customers.

Interface directly with clients throughout testing program and support clients in adhering to FDA regulatory requirements.

Establish appropriate supply of reagents and services, utilizing extensive knowledge in this area to communication effectively within organization and to vendors.

Selected Accomplishments

Established cGMP cell culture/virology laboratory which resulted in generating over $1 million in revenue from the first client, including gaining approval from senior management as well as the client, creating plan for laboratory setup, developing budget for equipment and supplies, determining personal needs and hiring process, developing and approving necessary documentation such as validation plans, protocols and SOPs, batch records, reports and overseeing equipment validation and qualifications, methods validation and qualification, trial testing, and lot release testing.

Doubled associated revenue from current and new clients by leading improvements and reestablishment of GLP in vivo testing program included different animal models.

Launched in vivo animal testing GLP program for over 50 news clients during tenure.

Contributed to the significantly improved GLP/GMP documentation.

Developed and implemented virology testing training program for management and technical staff.

Led over 50 new testing programs/projects during tenure and received monetary bonuses each year.

Beckman Coulter Inc., Chaska, MN, 08/2001 – 05/2004

Senior Development Scientist

Reporting to the Managing Director of R&D, researched and developed highly automated immunoassay systems for in vitro diagnostics of blood borne pathogens used in major hospitals and medical centers, diagnostic labs, and blood banks throughout the world.

Yuory V. Karetnyi M.D., Ph.D. Page 3

Managed projects for researching and developing FDA-approved diagnostic kits for automated immunoassay platform according to design control process including feasibility, design control, design transfer, validation, qualification, clinical trials and regulatory agency submission.

Controlled up to 4 R&D projects simultaneously, oversaw scientific and technical parts of FDA submissions to regulatory agencies, and provided scientific and technical support for new product launches.

Participated in 510k and PMA preparations for IVD products.

Responsible for experimental and format design, feasibility studies, screening validation and verification of antibodies and antigens, and development of appropriate documentation.

Modified and optimized immunoassays for blood borne infections (HAV, HBV, HCV and HIV).

Developed and optimized cardiac, autoimmune and cancer immunoassays (triponin, AFP, PSA, anti-cardiolipin and anti-phospholipid antibody).

Provided scientific and technical input for budget justifications to upper management, worked closely with manufacturing, quality assurance, quality control, regulatory and clinical departments, and provided technical support and troubleshooting to clients.

Selected Accomplishments

Lead team responsible for development, validation, clinical trials, FDA submission, and market launch of Alfa-Feto-Protein (AFP) immunoassay kits.

Developed immunoassay kits for viral hepatitis in vitro diagnostics.

Cancer Center, University of Iowa College of Medicine, Iowa City, IA, 08/1999 – 09/2001

Research Scientist

Responsible for immune and gene cancer therapeutics, gene transfer design, construction and development of viral and bacterial vectors for gene transfer, transcription and translation analysis, enhancement of anti-cancer immune

response, virus apoptosis induction as an adjuvant for anti-cancer therapy, and development of dendritic cell vaccines and anti-cancer DNA vaccines.

Broadened knowledge of cancer immunology and cell biology.

Parvovirus Laboratory, Division of Rheumatology, Dept. of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa

NIH Training Grant Fellow, 06/1997 – 07/1999

Houts-Arthritis Foundation Fellow, 02/1995 – 06/1997

Responsible for R&D and clinical diagnostic application of Immune Adherence PCR for detection of parvovirus B19 in human tissues.

Immobilized, isolated, amplified, cloned and genotyped Parvovirus B19 DNA.

Defined pathogenesis of Parvovirus B19 infection and characterized mechanisms of B19 association with liver diseases.

Transcription and translation analysis, specific viral mRNAs detection

Developed immunochemistry assays for demonstration of parvovirus B19 proteins and apoptosis in cell culture (immuno-cytochemistry, TUNEL assay).

Performed clinical diagnostics and isolation of hepatitis E virus infection and studied hepatitis E virus infection prevalence in the USA among humans and animals (zoonotic nature).

Development of rodent models for hepatitis E infection.

Responsible for molecular biology and modeling of hepatitis E virus infection and isolating, amplifying (RT-PCR) and genotyping of viral RNA.

Developed ELISA for detection anti-hepatitis E virus antibodies.

Served as PI and co-PI on grant applications for government and non-government agencies and organizations

Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Israel, 09/1991-01/1995

Senior Researcher, Hepatitis Group Leader

Performed molecular diagnostics, isolation and molecular epidemiology of hepatitis A and E viruses.

Responsible for R&D enzyme-immunoassay for detection antibodies to hepatitis A and E viruses

Demonstrated hepatitis E virus infection existence in Israel.

Achieved first isolation and genetic characterization of hepatitis A virus strains in Israel.

Yuory V. Karetnyi M.D., Ph.D. Page 4

Laboratory of Etiology & Diagnostics of Hepatitis, Institute of Poliomyelitis & Viral Encephalitides, Moscow, Russia, 02/1985 – 06/1991

Senior Research Scientist, Head of Immunoassay Group

Responsible for serology, clinical diagnostics and molecular biology of hepatitis A and E viruses, R&D development of ummunoassays, and transfer to manufacturing.

Modeled hepatitis A and E virus infections in vivo (primate, swine and rodent models) and in vitro (cell cultures) and demonstrated hepatitis E virus infection in rodents.

Led hepatitis A vaccine trials (immunoassay support), showed immunologic difference between human and simian hepatitis A strains, and designed techniques for screening clinical and environmental specimens for hepatitis A and E virus.

Laboratory of Viral Hepatitis, Clinical Department, D.I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, Moscow, Russia, 09/1983 – 02/1985

Researcher

Lead clinical trials for hepatitis B immunoglobulin (HBIG).

Studied vertical transmission of hepatitis B virus infection.

Developed of system for immunoscreening of pregnant women for hepatitis B virus infection and prophylaxis of vertical transmission.

Laboratory of Contamination, L.A. Tarasevitch State Research Institute of Standardization & Control of Medical Biological Preparations, Ministry of Health of Russia, Moscow, Russia (Russian FDA), 02/1981 – 09/1983.

Researcher

Developed new methods of co-cultivation permissive and non-permessive cells for detection of viral contamination in cell cultures of simian origin.

Skills

IVD- PCR, Immune PCR, DNA hybridization, various platforms for qRT-PCR (vial load –BKV, EBV, HAV, HCV, HIV, HBV, HSV1/2, Adenovirus, Human Parvovirus B19, Coxsackievirus, Influenza and other respiratory viruses), R&D of immunoassays (ELISA, RIA, immunochemistry, imminofrluoresence, immunoperoxidase assay, TUNEL assay, flowcytometry), virus propagation in cell culture and in vivo; virus purification; chromatography, ultrafiltration, infectivity assays; hybridization techniques; Southern, Northern and Western blotting, cloning and sequencing, transfection and transduction of mammalian cells. Safe handling of radioisotopes and blood-borne pathogens.

Education

PhD in Virology, L.A. Tarasevitch State Research Institute of Standardization & Control of Medical Biological Preparations, Ministry of Health of Russia, Moscow, Russia.

M.D., I.M. Sechenov Moscow Medical Academy (former 1st Moscow Medical Institute), Moscow, Russia

Specialization in Virology (M.S.Trainee), Lab. of Viral Ontogenesis, D.I. Ivanovsky Institute of Virology, Russian Academy of Medical Sciences, Moscow Russia.

Major: Metabolism of cells infected with equine encephalomyelitis virus. Work granted by 1st Award of the All Soviet Union Competition Graduated Students’ Scientific Works.

Affiliations

Full Member of American Society for Virology – 1995

A Member of the International Society for Antiviral Research - 2007

Publications

Original Articles

1.Karetnyi, Y.V., Elekoev, K.A., Shalunova, N.V., Dzagurov, S.G.: The Techniques for Improvement of the Methods of Controlling the Cell Cultures of Simian Origin for Cytomegalovirus Contamination. Viruses and Viral Infections in Humans, 1981,Moscow, p. 63

2.Kolomietz, O.L., Karetnyi, Y.V. The Electron Microscopic Investigation of the Cytopathic Effect Caused by Cytomegalovirus in African Green Monkey Kidney Cells and in Human Embryonic Fibroblasts. Standards, Strains and Methods for Control of Bacterial and Viral Preparations, 1981, Moscow,, 1981, pp.43-44.

Yuory V. Karetnyi M.D., Ph.D. Page 5

3.Elekoev, K.A., Shalunova, N.V., Dzagurov, S.G., Pasca, A., Karetnyi, Y.V. The Application of the Indirect Immunofluorescence For Detecting The Antibodies to Cytomegalovirus. Laboratornoe Delo, 2:251-252, 1982.

4.Karetnyi, Y.V., Elekoev, K.A., Shalunova, N.V., Dzagurov, S.G.: Use of Co-cultivation Method for Detection of Viral Contamination in the Cell Cultures of Simian Origin. Voprosi Virusologii, 2:199-205, 1982.

5.Elekoev, K.A., Karetnyi, Y.V. The Comparison of Three Different Methods for Detection of the Antibodies to Cytomegalovirus in the Monkey’s Sera. Standards, Strains and Methods for Control of Bacterial and Viral Preparations, 1983, Moscow, p.85.

6.Kuzin, S.N., Karetnyi, Y.V. Detection of Markers of HBV-infection In Pregnant Women in Moscow. Molecular Biology of Viral Hepatitis, 1987, Moscow.

7.Kuzin, S.N., Shakhgildyan I.V., Farber, N.A., Mikhailov M.I., Vorozbieva, T.E., Karetnyi, Y.V., Braginski, D.M., Abramovich, R.A., Martinov, K.A., Sokolova, N.V, Golosova, T.V., Margolina, A.N., Malina, I.D., Kalinichenko, T.V.: Hepatitis B Virus Infection Markers in Babies Born to Mothers Carriers of HBs Antigen in the Presence of Anti-HBe and the Problems of Passive Immunoprophylaxis. Voprosy Virusologii, 1:59-63, 1987.

8.Andzhaparidze, A.G., Karetnyi, Y.V., Orlova, T.I., Bradley, D.W., Balayan, M.S.: Differentiation of Human and Simian HAVs by Mono- and Polyclonal Antibodies. Hepatitis Scientific Memoranda, 7:80-83, 1987.

9.Karetnyi, Y.V., Kuzin, S.N., Sychev, A.V., Balayan, M.S.: Transplacental Antibodies to Hepatitis A. Voprosy Virusologii, 1:86-89, 1988.

10.Prikazchikov, S.A., Karetnyi, Y.V., Vakar, E.I., Balayan, M.S., Zenkov, V.A., Postovi, P.P., Sobina, G.V., Sysolyatin, V.A., Alekseeva, L.D., Zaselyaeva, N.D., Tsvetova, G.V.: Futures of Formation of Humoral Immunity to Hepatitis A in Groups of Children’s Day-care Centers., Voprosy Virusologii, 2:169-173, 1988.

11.Zamyatina, N.A., Andzhaparidze, A.G., Balayan, M.S., Sobol, A.V., Titova, I.P., Karetnyi, Y.V., Poleshuk, V.F.: Development Infection in Monkeys as a Result of Successive Natural and Experimental Infection with Hepatitis A Virus. Voprosy Virusologii, 2:122-12

12.Karetnyi, Y.V., Vasilyeva, Z.N., Balayan, M.S., Zenkov, V.A., Sysolyatin, G.V., Lysenko, G.V., Tsvetova, G.V., Tesheva, S.C., Klimenko, L.A., Mktrchan, M.O. Development of the Epidemiological Process and the Formation of Humoral Immunity to Hepatitis A Virus in Adolescent’s Communities. Journ. Microbiol. Epidemiol. Immunol., 10:71-76, 1990.

13.Kuzin, S.N., Ikoev, V.N., Shakhgildyan, I.V., Gorbunov, M.A., Farber, N.A., Mikhailov, M.I., Braginshky, D.M., Karetnyi, Y.V. Regularities of Perinatal Infection with Hepatitis B Virus in Territories with Different levels of Hbs- and HBe-Ag Carrier State. Voprosy Virusologii, 4:304-306, 1990.

14.Karetnyi, Y.V., Dzhumalieva, D.I., Usmanov, R.K., Titiova, I.P., Litvak, Y.I., Balayan, M.S.: Probable Involvement of Rodents in the Spread of Viral Hepatitis E. Journ. Microlbiol. Epidemiol. Immunol., 4:52-56, 1993.

15.Kovalev, O.B., Kaganov, B.S., Karetnyi, Y.V., Uchaikin, V.F. Features of Specific Humoral Immune Response During Acute and Prolonged Course of Viral Hepatitis A in Children. Pediatria, 6:23-26, 1993.

16.Karetnyi Y. V., Favorov, M.O., Khudyakova, N.S., Weiss, P., Bar-Shani, S., Handsher, K., Aboudy, Y., Varsano, N., Schwartz, E., Levin, E., Mendelson, E., Fields, M.: Serological Evidence for Hepatitis E Virus Infection in Israel. J. Med Vrol, 45:316-320, 1995.

17.Karetnyi, Y.V., Mendelson, E., Shlyakov, E., Rubinstein, Goldybev, N., Levin, R., Sanler, M., Schreiber, M., Rubinstein, U., Shif, I., Handsher, R., Varsano, N., Modan, B.: Prevalence of Antibodies Against Hepatitis A Virus Among New Immigrants in Israel. J Med Vrol, 46:61-65, 1995.

18.Karetnyi, Y.V., Favorov, M.O., Khudyakova, N.S., Bar-Shani, S., Dogan, R., Fields, H.A., Mendelson, E. Populations With High Prevalence of Antibody Against Hepatitis E Virus in Israel. Clin. Diagnostic Virology, 6:73-76, 1996.

19.Naides, S.J. Karetnyi, Y.V., Cooling, l.l.W, Markin, R.S., Langas A.N. Human Parvovirus B19 infection and Hepatitis. Lancet, 347:1563, 1996

20.Karetnyi Y.V., Beck P.R., Markin R.S., Langas A.N., Naides S.J. Human Parvovirus B19 in Acute Fulminant liver Failure Arch. Virol. 144: 1713-1724, 1999

21.Linder N., Karetnyi Y.V., Gidony Y., Ohel G., Levin E., Kuint J., Davidovich N., Gidony I., Mendelson E., Barzelai, A. Placental Transfer of Hepatitis A Antibodies in Full Term and Preterm Infants. Pediatric Infect. Dis. J. 16: 245-247, 1999

22.Karetnyi Y.V., Gilchrist M., Naides S.J. Hepatitis E Virus Infection Pevalence Among Selected Populations In Iowa. J. Clin. Virol. 14: 51-55, 1999

23.Poole B.D., Karetnyi Y.V., Naides S.J. Parvovirus B19-Induced Apoptosis of Hepatocytes. J.Virol.,78(14):7775-83, 2004

Yuory V. Karetnyi M.D., Ph.D. Page 6

National and International Conferences Abstracts

1.Karetnyi, Y.V., Malina, I.D., Kalinichenko, I.V. The Frequency of Carrier State of HBV Markers Between Pregnant Women. Proceedings of the IX Ukrainian Meeting of Microbiologists, Epidemiologists and Parasitologists, 1985, Kiev., vol.I, p.65.

2.Demidenko, T.P., Karetnyi, Y.V., Vinogradova, E.N. Prognostic Significance of the Determination of Specific Hepatitis A Virus Markers. Proceedings of the International Symposium “Viral Hepatitis”, September 3-8, 1990, Rostov-Moscow, USSR. Results of Science and Techniques 2:6-7, 1990.

3.Karetnyi Y.V. Formation of Humoral Immunity to Hepatitis A Virus in the Adolescent’s Communities of Different Geographical Regions. Proceedings of the International Symposium “Viral Hepatitis”, September 3-8, 1990, Rostov-Moscow, USSR. Results of Science and Techniques 2:6-7, 1990.

4.Djumalieva, D.I., Alimbaeva, A.B., Usmanov, R.K., Karetnyi, Y.V. Study of the Etiology of Viral Hepatitis Outbreaks in the Region of Osh Town (Kirghizia) by ImmuneElectron Microscopy. Abstr. 4th Regional Conference. “Current Problems in Epidemiology & Hygiene”, Osh, Kirghizia, 1989, p.44-46.

5.Kovalev, O.B., Koganov, B.S., Karetnyi, Y.V., Levina, E.I., Dygay, I.G., Konev, V.A., Galkina, Y.A. Clinical Variants of Course and Outcome of Verified Hepatitis A in Childhood. Proceeding of All-Russian Symposium of Infectious Diseases, Suzdal, September, 1992, Moscow-Kirov, 1:108-114, 1992.

6.Karetnyi, Y.V., Favorov, M.D., Khudyakov, Y.E., Fields, M.A., Margolis, M.S., Bar-Shani, S., Schwartz, E., Weiss, P., Mendelson, E. Serological Evidence for Hepatitis E Virus Infection in Israel. Abstracts of 1994 Joint Meeting of European Group for Rapid Diagnosis and Society Against Virus Diseases, August 14-18, 1994, Stockholm, Sweden. “Progress in Clinical Virology”, p. 218 (#p4/13).

7.Karetnyi, Y.V., Mendelson, E., Shlyakov, E., Rubinstein, E., Golubev, N., Levin, R., Sandler, M., Shreiber, M., Rubinstein, U., Shif, I., Handsher, R., Varsano, N., Modan, B. Prevalence of Antibodies Against Hepatitis

A Virus Among New Immigrants in Israel. Proceedings of the Annual Meeting of the Israeli Society for Microbiology, February 1995, Haifa, Israel.

8.Karetnyi, Y.V., Favorov, M.D., Khadyakova, H.S., Weiss, P., Bar-Shani, S., Handsher, R., Aboudy, Y., Varsano, N., Schwartz, E., Levin, E., Dagan, R., Fields, M., Mendelson, E. Proceedings of the Annual Meeting of the Israeli Society for Microbiology, February 1995, Haifa, Israel.

9.Barzelay, A., Schulman, S., Karetnyi, Y.V., Levin, E., Weiss, P., Vazon, D., Martinowitz, U. Hepatitis E Virus Infection in Hemophiliacs. Proceedings of International Symposium “Liver Diseases in Hemophilia, New Directions in Diagnosis, Management, and Treatment” March 3-5, 1995, Atlanta,Georgia.

10.Linder, N., Karetnyi, Y.V., Gidoni, Y., Handsher, R., Mendelson, E., Levin, E., Barzelay, H.: Transplacental Transfer of Hepatitis A Antibodies to Premature Infants. Proceedings of the Meeting of American Sci. for Pediatric Research, May 7, 1995, San Diego, California..

11.Karetnyi, Y.V., Favorov, M.O., Khudyakova, N.S., Weiss, P., Bar-Shani, S., Handsher, R., Aboudy, Y., Narsano, N., Schwartz, E., Levin, E., Dagan, R., Fields, H., Mendelson, E. Prevalence of Antibodies to Hepatitis E. Virus in Israel: Populations with low and high prevalence and evidence for local infection. Abstracts, 95th General Meeting of the American Sci. for Microbiology, May 21-25, 1995, Washington, D.C., p.584 (T-14).

12.Langas A.N., Markin R.S., Cattral M., Karetnyi Y., Cooling L.L.W., Koener T.A.W., Naides S.J. Parvovirus B19 as a Possible Cause of Acute Liver Failure: Clinical And Molecular Evidence. Abstracts of the 46th Annual Meeting of the American Association for the Study of Liver Diseases, November 3-7, 1995, Chicago, IL, USA, Hepatology, 1995, 22 (40), part 2, p.444A, abstr. #1351.

13.Karetnyi Y.V., Beck P.R., Langas A.N.,Markin R.S., Naides S.J. Possible Involvement of Parvovirus B19 in Non-A, Non-B, Non-C Acute Liver Failure: Demonstration of the Virus in Liver by Immune-Adherence PCR (IA-PCR). Abstracts of the 3-d Annual Bristol-Myers Squibb International Symposium on Molecular Pathogenesis of Viruses, New York, NY, USA.

14.Naides, S.J., Karetnyi, Y.V., Beck, P.R., Langnas, A.N., and Markin, R.S.: Parvovirus B19 as an Etiologic Agent of Fulminant Non-A, Non-B, Non-C, Non-E Hepatitis (HNA-E): Evidence for Productive Viral Infection. American Society for Investigative Pathology, New Orleans, June 1-5, 1996.

15.Karetnyi Y.V., Beck P.R., Langas A.N.,Markin R.S., Naides S.J. Parvovirus B19 As an Etiologic Agent of Fulminant Non-A, Non-B, Non-C, Non-E Hepatitis (HNA-E): Evidence For Productive Viral Infection. Abstracts of the 15th Annual Meeting of American Society For Virology, London, Ontario, Canada, 1996, p. 140 (Abs.#W33-2).

Yuory V. Karetnyi M.D., Ph.D. Page 7

16.Karetnyi, Y.V., Parker, D.W., Langnas, A.N., Markin, R.S., and Naides,S.J.:Hepatotropic Genetic Variant(s) of Human Parvovirus B19 as Etiologic Agent(s) Causing Non-A, Non-B, Non-C, Non-E Fulminant Hepatitis (FNNA-E). Xth International Congress of Virology, Jerusalem, Israel, August 11-16, 1996. (ABS # W59-1, p.84).

17.Manor Y., Handsher R., Karetnyi Y.V., Slater P., Vansover A., Shulman L.N., Mendelson E.Searching For Polio and Hepatitis A Viruses in the Environment-The Israeli experience. Xth International Congress of Virology, Jerusalem, Israel, August 11-16, 1996. (Abs. # W15-5, p. 28).

18.Raju G.S., Karetnyi Y.V., Naides S.J., Martin M., Mitros F., LaBrecque D.R., Parvovirus B19 Infection in Adults Following Orthotopic Liver Transplantation (OLT) Abstracts of the 47th Annual Meeting of the American Association for the Study of Liver Diseases, November 8-12, 1995, Chicago, IL, USA, Hepatology, 1996, 24 (4), part 2, p.565A, abstr. #1754.

19.Karetnyi Y.V., Cooling L.l.W., Kirchman D.A., Seftor E.A., Hendrix M.J.C., Fox I., Markin R.S., Langnas A.N., Naides S.J. Cultivation of Human Parvovirus B19 Isolates Derived From Blood and Liver in Non-hemapoetic Cell Lines. Abstracts of the 16th Annual Meeting of American Society For Virology, Bozeman, Montana, 1997, p. 159 (Abs. #W35-6).

20.Naides S.J., Karetnyi Y.V., Voigt m.D., Vorhies M.L., Martin M., LaBrecque D.S. Parvovirus B19 Infection in Liver Transplantant Patients. Abstracts of the 16th Annual Meeting of American Society Bozeman, Montana, 1997, p. 224 [Abs. #P24-14).

21.Naides, S.J., Karetnyi, Y.V., Voigt, M.D., Vorhies, M.L., Martin, M., and LaBrecque, D.S.: Parvovirus B19 Infection in Post-Liver transplantation Patients. VIIth International Parvovirus Workshop and 1st Euroconference on Health Benefits and Risks from Parvovirus Infection, Heidelberg, Germany, September 3-7, 1997.

22.Karetnyi Y.V., Khudyakov Y.V., Fields H., Gilchrist M., Naides S.J. Prevalence of Antibodies Against Hepatitis E Virus (Anti-HEV) among selected Populations in Iowa. Abstracts of the 17th Annual Meeting of American Society, Vancouver, British Columbia, Canada, 1998, p.142 (Abs.#W46-6)

23.Karetnyi Y.V., Beck P.R., Langas A.N.,Markin R.S., Naides S.J. Parvovirus B19 As a Possible Etiologic Agent of Fulminant Non-A, Non-B, Non-C, Non-E Hepatitis. All Russia Meeting of Pediatrics, Moscow, Russia, 1998, p198. \

24.Workshop and 1st Euroconference on Health Benefits and Risks from Parvovirus Infection, Heidelberg, Germany, September 3-7, 1997.

25.Karetnyi Y.V., Khudyakov Y.V., Fields H., Gilchrist M., Naides S.J. Prevalence of Antibodies Against Hepatitis E Virus (Anti-HEV) among selected Populations in Iowa. Abstracts of the 17th Annual Meeting of American Society, Vancouver, British Columbia, Canada,1998, p.142 (Abs.#W46-6).

26.Karetnyi Y.V., Beck P.R., Langas A.N.,Markin R.S., Naides S.J. Parvovirus B19 As a Possible Etiologic Agent of Fulminant Non-A, Non-B, Non-C, Non-E Hepatitis. All Russia Meeting of Pediatrics, Moscow, Russia, 1998, p198.

Books and Reviews

1.Karetnyi, Y.V., Elekoev, K.A., Shalunova, N.V.: The Indirect Immunofluorescence for Detection of the Antibodies to the Simian Cytomegalovirus. Methodical Recommendations of the Ministry of Health of the USSR, 1982, Moscow.

2.Karetnyi, Y.V., Elekoev, K.A., Shalunova, N.V.: The Use of Co-cultivation method for Detection of Herpesviruses in the Primary African Green Monkey Kidney Cell Cultures. Methodical Recommendations of the Ministry of Health of the USSR, 1982, Moscow.

3.Karetnyi, Y.V. Development of Methods for Indication of Simian Herpesviruses. Dissertation of the Candidate of Medical Sciences Degree (Ph.D. in Virology), 1983, Moscow.

4.Balayan, M.S., Karetnyi, Y.V. Atypical forms and Outcomes of Viral Hepatitis A. (Scientific Review). Klinicheskaya Meditsina, 3:39-44, 1987.

5.Karetnyi Y.V., Naides S.J. Parvovirus B19 in: Manual of Laboratory Immunology, 5th Edition. Lane, H.C. Specter S. (Eds.), ASM Press. Washigton D.C. 1996

6.Karetnyi Y.V., Naides S.J. Parvovirus B19 in: Manual of Laboratory Immunology, 6th Edition. Lane, H.C. Specter S. (Eds.

Contact this candidate